全文获取类型
收费全文 | 218734篇 |
免费 | 12031篇 |
国内免费 | 6294篇 |
专业分类
耳鼻咽喉 | 2760篇 |
儿科学 | 8278篇 |
妇产科学 | 2971篇 |
基础医学 | 16407篇 |
口腔科学 | 4168篇 |
临床医学 | 26674篇 |
内科学 | 39077篇 |
皮肤病学 | 3016篇 |
神经病学 | 11016篇 |
特种医学 | 12164篇 |
外国民族医学 | 22篇 |
外科学 | 32961篇 |
综合类 | 19325篇 |
现状与发展 | 25篇 |
预防医学 | 14501篇 |
眼科学 | 4400篇 |
药学 | 23714篇 |
79篇 | |
中国医学 | 4475篇 |
肿瘤学 | 11026篇 |
出版年
2023年 | 1874篇 |
2022年 | 3681篇 |
2021年 | 8924篇 |
2020年 | 5148篇 |
2019年 | 11058篇 |
2018年 | 5643篇 |
2017年 | 4874篇 |
2016年 | 6868篇 |
2015年 | 9739篇 |
2014年 | 17743篇 |
2013年 | 15423篇 |
2012年 | 18855篇 |
2011年 | 15591篇 |
2010年 | 14398篇 |
2009年 | 13973篇 |
2008年 | 12551篇 |
2007年 | 12617篇 |
2006年 | 10628篇 |
2005年 | 6959篇 |
2004年 | 3403篇 |
2003年 | 2970篇 |
2002年 | 2400篇 |
2001年 | 1893篇 |
2000年 | 1710篇 |
1999年 | 1032篇 |
1998年 | 1456篇 |
1997年 | 1326篇 |
1996年 | 1121篇 |
1995年 | 1177篇 |
1994年 | 1149篇 |
1993年 | 889篇 |
1992年 | 1103篇 |
1991年 | 990篇 |
1990年 | 1031篇 |
1989年 | 1010篇 |
1988年 | 939篇 |
1987年 | 824篇 |
1986年 | 673篇 |
1985年 | 1583篇 |
1984年 | 1738篇 |
1983年 | 1258篇 |
1982年 | 1343篇 |
1981年 | 1332篇 |
1980年 | 1146篇 |
1979年 | 985篇 |
1978年 | 759篇 |
1977年 | 760篇 |
1976年 | 661篇 |
1974年 | 455篇 |
1973年 | 433篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
63.
《Cirugía espa?ola》2022,100(11):709-717
ObjectiveMost evidence, including recent randomized controlled trials, analysing anal squamous cell carcinoma (SCC) do not consider immunocompromise patient population. The aim of this study was to compare clinical and oncological outcomes among immunocompetent and immunocompromised patients with anal squamous cell carcinoma.MethodMulticentric retrospective comparative study including 2 cohorts of consecutive patients, immunocompetent and immunocompromised, diagnosed with anal SCC. This study evaluated clinical characteristics, clinical response to radical chemoradiotherapy (CRT) and long-term oncological results including both local and distant recurrence, overall survival (OS) and disease-free survival (DFS).ResultsA total of 84 patients, 47 (55.6%) female, diagnosed with anal SCC from January 2012 to December 2017 were included, 22 (26%) and 62 (74%) patients in immunocompromised and immunocompetent groups respectively. Patients in immunocompromised group were significantly younger (53 vs. 61 years; P=0.001), with smaller tumoral size (P=0.044) and reported higher rates of substance abuse.including tobacco use (P=0.034) and parenteral drug consumption (P=0.001). No differences were found in administered therapies (P=301) neither in clinical response to chemoradiotherapy (83 vs. 100%). Moreover, similar 5-year OS (60 vs. 64%; P=0.756) and DFS (65 vs. 68%; P=0.338) were observed.ConclusionThe present study shows no significant differences in long-term oncological results among immunocompetent and immunocompromised patients diagnosed with anal SCC, with a similar oncologic treatment. This evidence might be explained due to the close monitoring and adequate therapeutic control of HIV positive patients. 相似文献
64.
65.
66.
67.
68.
《Vaccine》2022,40(24):3320-3329
BackgroundCurrently, booster dose is needed after 2 doses of non-live COVID-19 vaccine. With limited resources and shortage of COVID-19 vaccines, intradermal(ID) administration might be a potential dose-sparing strategy.ObjectiveTo determine immunologic response and reactogenicity of ID ChAdOx1 nCoV-19 vaccine (AZD1222,Oxford/AstraZeneca) as a booster dose after completion of 2-dose CoronaVac(SV) in healthy adult.MethodsThis is a prospective cohort study of adult aged 18–59 years who received 2-dose SV at 14–35 days apart for more than 2 months. Participants received ID AZD1222 at fractional low dose(1×1010 viral particles,0.1 ml). Antibody responses were evaluated by surrogate virus neutralization test(sVNT) against delta variant and wild type, and anti-spike-receptor-binding-domain immunoglobulin G(anti-S-RBD IgG) at prior, day14, 28, 90, and 180 post booster. Solicited reactogenicity was collected for 7 days post-booster. Primary endpoint was the differences of sVNT against delta strain ≥ 80% inhibition at day14 and 90 compared with the parallel cohort study of 0.5-ml intramuscular(IM) route.ResultsFrom August2021, 100 adults with median age of 46 years(IQR 41–52) participated. Prior to booster, geometric mean(GM) of sVNT against delta strain was 22.4% inhibition(95 %CI 18.7–26.9) and of anti-S-RBD IgG was 109.3 BAU/ml(95.4–125.1). Post ID booster, GMs of sVNT against delta strain were 95.5% inhibition (95%CI 94.2–96.8) at day14, 73.1% inhibition (66.7–80.2) at day90, and 22.7% inhibition (14.9–34.6) at day180. The differences of proportion of participants achieving sVNT against delta strain ≥ 80% inhibition in ID recipients versus IM were + 4.2% (95 %CI -2.0to10.5) at day14, and ?37.3%(-54.2to-20.3) at day90. Anti-S-RBD IgG GMs were 2037.1 BAU/ml (95%CI 1770.9–2343.2) at day14 and 744.6 BAU/ml(650.1–852.9) at day90, respectively. Geometric mean ratios(GMRs) of anti-S-RBD IgG were 0.99(0.83–1.20) at day14, and 0.82(0.66–1.02) at day90. Only 18% reported feverish, compared with 37% of IM (p = 0.003). Common reactogenicity was erythema at injection site(53%) while 7% reported blister.ConclusionLow-dose ID AZD1222 booster enhanced lower neutralizing antibodies at 3 months compared with IM route. Less systemic reactogenicity occurred, but higher local reactogenicity. 相似文献
69.
《HPB : the official journal of the International Hepato Pancreato Biliary Association》2022,24(10):1780-1788
BackgroundWe assessed whether or not covalently closed circular DNA (cccDNA) levels in the background liver influence the recurrence of hepatocellular carcinoma (HCC) in patients with resolved hepatitis B virus (HBV) infection.MethodsAmong 425 patients who underwent initial hepatectomy for HCC between 2010 and 2018, a retrospective review was performed in 44 with resolved HBV infection. The clinicopathologic characteristics were analyzed for correlation with tumor recurrence. The HBV cccDNA levels were tested via a droplet digital polymerase chain reaction assay.ResultsHBV cccDNA was detected in 27 of 44 patients (61%), and the median level was 1.0 copies/1000 ng (range, 0-931.3 copies/1000 ng). Anti-HBc ≥8.9 S/CO was associated with cccDNA detection (odds ratio, 11.08; 95% confidence interval [95% CI], 2.48-49.46; P = 0.002). Twenty-eight patients (64%) developed HCC recurrence after hepatectomy. The overall 3- and 5-year recurrence-free survival rates were 45.7% and 34.3%, respectively.19 HBV cccDNA levels was not significantly associated with HCC recurrence, while the presence of multiple tumors was an independent risk fact or (hazard ratio, 6.53; 95% CI, 2.48-17.19; P < 0.001.ConclusionHBV cccDNA levels did not influence HCC recurrence after hepatectomy. Anti-HBc levels may be used as a surrogate marker for cccDNA. 相似文献
70.